Healius logo
HLS

Healius

Health Care Equipment & Services

Healius is a leading Australian diagnostics company providing essential healthcare services through a vast network of labs and diagnostic centers. With a focus on accessible and affordable healthcare, Healius leverages digital technologies to enhance service delivery and patient care.

Short position

short percentage2.54%
reported shorts18.4M
shares on issue726.179M

Healius (ASX:HLS) has 2.54% of its shares on issue reported as short positions as of 5 Oct 2026, or about 18,426,064 shares. Over the past 30 days that figure has fallen 5.72 percentage points, and over 90 days it has fallen 7.48 percentage points. Its highest recorded short interest was 10.81% in June 2026. HLS is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Healius (HLS) financials

Results, ratios and statements

Latest result

Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency

Revenue
$1.37B (source: ASX (Markit))vs $1.34B (FY25)
ASX (Markit), as at 29 Sep 2026
NPAT
−$415.6M (source: ASX (Markit))vs −$151.2M (FY25)
ASX (Markit), as at 29 Sep 2026
EPS (diluted)
−$0.57vs −$0.21 (FY25)
Yahoo Finance, as at 29 Sep 2026
Rev YoY
+2.2%FY
EPS YoY
n/aFY
  • ASX (Markit)

Summary of 2026 Annual Report, 23 Sep 2026

Healius reported FY2026 underlying revenue up 2.1% to $1.37 billion and underlying EBITDA up 8.1% to $258.6 million, with underlying EBIT surging 76.6% to $30.2 million. No dividend was declared for the year. The company expects continued growth in specialised diagnostics into FY2027, citing strong contributions from Agilex, Genomic Diagnostics, and Vetnostics.

Automated summary of the filing; the filing itself is the record.

Key ratios

Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026

Gross margin
85.0%
Operating margin
2.2%
Net margin
−30.3%
FCF margin
12.2%
ROE
n/a
ROA
n/a
FCF conversion
n/a
Net debt (excl. leases)
n/a
Net debt / EBITDA
n/a
Current ratio
n/a
Interest cover
7.9×
Cash dividends paid / net profit
n/a
Market cap
n/a (no share count we can vouch for)
P/E
n/a
P/B
n/a (no share count we can vouch for)

Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance, ASX (Markit) and Derived: trailing 12 months at year end, as at 29 Sep 2026.

Financial statements

Figures in AUD, the reporting currency; Yahoo Finance unless marked

HLS income, newest period first, figures in AUD
Line itemFY26FY25FY24FY23
Revenue$1.37B (source: ASX (Markit))$1.34B$1.75B$1.71B
Gross profit$1.17B (source: Derived: trailing 12 months at year end)$1.13B$1.52B$1.48B
Operating income$30.2M (source: Derived: trailing 12 months at year end)$200.0K$65.5M$98.1M
EBITDA−$145.8M (source: Derived: trailing 12 months at year end)−$341.5M−$338.9M−$91.5M
EBIT−$374.2M (source: Derived: trailing 12 months at year end)−$565.8M−$620.1M−$368.7M
Interest expense$3.8M (source: Derived: trailing 12 months at year end)$26.3M$30.0M$28.6M
Pretax income−$378.0M (source: Derived: trailing 12 months at year end)−$592.1M−$650.1M−$397.3M
Tax$30.9M (source: Derived: trailing 12 months at year end)−$29.1M−$14.1M−$17.3M
NPAT−$415.6M (source: ASX (Markit))−$151.2M−$645.8M−$367.8M
Net interest income−$49.1M (source: Derived: trailing 12 months at year end)−$65.1M−$70.8M−$62.3M
EPS basic−$0.57−$0.21−$0.98−$0.60
EPS diluted−$0.57−$0.21−$0.98−$0.60
Sharesn/a726.1M726.1M615.3M
  • ASX (Markit)
  • Derived: trailing 12 months at year end